This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Chemours (CC) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Chemours (CC) stock is a good choice for value-oriented investors right now from multiple angles.
Chemours (CC) Down 2.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
With Equities on a Roll in 2019, a Quiet Week Leads to More Gains
by David Borun
The rally rolls on during a holiday-shortened week
Chemours (CC) Q4 Earnings In Line, Revenues Trail Estimates
by Anindya Barman
Lower volumes affected Chemours' (CC) results in Q4. The company sees adjusted earnings per share in the range of $4.00-$5.05 for 2019.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Our proven model does not show that Chemours (CC) is likely to beat estimates this quarter.
Friday Rally Helps the Markets Recover Earlier Weekly Losses
by David Borun
Positive earnings data and an end to the government shutdown help keep the 2019 rally gooing
Solid Gains Top Another Wild Week
by David Borun
A big selloff on Thursday is followed by an even bigger rally on Friday.
Chemours' Opteon XL41 Chosen by Carrier to Replace R-410A
by Zacks Equity Research
Chemours (CC) is committed to deliver world-class technology that reduces impact on global climate change.
Why Is Chemours (CC) Down 18.5% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) to Increase Prices of Methylamines Products
by Zacks Equity Research
Chemours' (CC) latest price hike is likely to support its margins.
Chemours (CC) Q3 Earnings Beat, Revenues Trail Estimates
by Zacks Equity Research
Chemours' (CC) Q3 results benefits from strong demand in Fluoroproducts and higher global average selling prices in Titanium Technologies.
Chemours (CC) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 7.97% and -5.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Fantastic Earnings Charts to Finish the Week
by Tracey Ryniec
Earnings season is still rocking and rolling with some of the biggest companies in the world reporting this week.
Chemical Stock Earnings Slated on Nov 1: DWDP, CC, PAH & ICL
by Anindya Barman
Investors should check these chemical stocks before their quarterly results as the industry is expected to sustain the momentum in Q3.
What's in the Offing for Chemours (CC) in Q3 Earnings?
by Anindya Barman
While Chemours (CC) faces headwinds from raw material and distribution costs, it is likely to gain from higher demand and prices in Q3.
Chemours (CC) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Should Value Investors Consider Chemours (CC) Stock Now?
by Zacks Equity Research
Let's see if The Chemours Company (CC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The Key to Spotting a Value Trap
by Tracey Ryniec
Just because a stock sinks and has a low P/E, doesn???t mean it's a value stock. Learn how to spot a true value stock from a value trap.
Chemours (CC) Earnings, Revenues Trump Estimates in Q2
by Anindya Barman
Chemours (CC) topped expectations in Q2 on strong results across its business segments.
Chemours (CC) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 11.76% and 0.76%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cabot (CBT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot (CBT) is likely to see year-over-year revenue growth in Q3.
Mosaic (MOS) to Post Q2 Earnings: What's in the Cards?
by Anindya Barman
Strong expected segment performance is likely to support Mosaic's (MOS) Q2 results.
LyondellBasell's (LYB) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LyondellBasell (LYB) expects to benefit from continued high operating rates in Q2. However, scheduled maintenance may weigh on results.
Chemical Stock Q2 Earnings Slated on Aug 2: DWDP, WLK & More
by Anindya Barman
Chemical companies are likely to gain from strategic actions and a favorable demand environment in Q2.